Global Team of Cancer Genetic Specialists Provides New Guidance for Individuals with PALB2 Gene Variants: ACMG Clinical Practice Resource to Help Guide Clinical Management of Patients at Increased Risk of Breast, Pancreatic and Ovarian Cancers
(ACMG) May 11, 2021 - The American College of Medical Genetics and Genomics (ACMG) has released an important new clinical practice resource from a global team of specialists in cancer genetics that will help inform the clinical management of patients who are at increased risk of breast cancer, pancreatic cancer and likely ovarian cancer.
New Drug Class Gives Hope To Some Ovarian Cancer Patients
(UW Medicine) May 3, 2021 - A study published today shows that the drug rucaparib has been effective in treating certain types of ovarian cancers if used early in treatment, after a diagnosis, and before the cancer cells build up a resistance to chemotherapy.
Mereo BioPharma and Cancer Focus Fund Announce Partnership for Phase 1b/2 Study of Etigilimab in Clear Cell Ovarian Cancer
(Yahoo! Finance) Apr 30, 2021 - Mereo BioPharma Group plc and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, today announced a partnership to evaluate Mereo’s lead anti-TIGIT therapeutic antibody candidate, etigilimab, in clear cell ovarian cancer.
Drug Derived from Kentucky-Grown Plant Shows Promise for Ovarian Cancer Treatment, Study Shows
(UK Healthcare) Apr 20, 2021 - A new study from University of Kentucky Markey Cancer researchers shows that Artemisia annua, a plant that has been traditionally used for its anti-malaria components, shows promise in treating ovarian cancer.
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
(Markets Insider) Apr 27, 2021 - U.S. FDA granted Fast Track Designation in 2018. Trial expected to enroll 300-400 patients at approximately 165 Sites in the U.S. and Europe in simplified adaptive trial design.
Evaluating Single Agent PARP Inhibitors or Combination Therapies for Maintenance Treatment of Ovarian Cancer
(Pharmacy Times) Apr 16, 2021 - Olaparib and niraparib both show promise in the maintenance treatment of ovarian cancer, though they may each be appropriate for different patient populations.
TILT Biotherapeutics and MSD to Collaborate on Clinical Trial of Adenoviral Cancer Immunotherapeutic TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer
(Yahoo! Finance) Apr 14, 2021 - TILT Biotherapeutics today announced a clinical trial collaboration agreement with MSD to evaluate TILT’s adenoviral cancer immunotherapy TILT-123, a dual cytokine armed oncolytic adenovirus, in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in a Phase I dose escalation trial in platinum resistant or refractory ovarian cancer.
Ovarian Cancer Patients Face Increased Risk of Mental Illness
(AACR) Apr 10, 2021 - Women diagnosed with ovarian cancer were more than three times more likely than the general public to be diagnosed with mental illnesses such as anxiety, depression, and adjustment disorder, according to results presented during Week 1 of the virtual AACR Annual Meeting 2021, held April 10-15.
Mersana Therapeutics Announces Initiation of UPLIFT Single-Arm Registration Strategy for UpRi in Platinum-Resistant Ovarian Cancer
(Yahoo! Finance) Apr 9, 2021 - Mersana Therapeutics, Inc. today announced the initiation of patient dosing in UPLIFT, a single-arm registration strategy to evaluate the safety and efficacy of upifitamab rilsodotin (UpRi, XMT-1536) in patients with platinum-resistant ovarian cancer who have received up to four lines of therapy.
Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA’s Expanded Access Pathway
(Yahoo! Finance) Apr 8, 2021 - Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced that an ovarian cancer patient has begun treatment with Atossa’s proprietary oral Endoxifen.